PEGASYS
-
Opinions on drugs -
Posted on
Mar 15 2006
- Updated on
Feb 19 2009
Reason for request
Extension of indication in the treatment of HBeAg positive or negative chronichepatitis B in adults with compensated liver disease.Extension of indication in the treatment of chronic hepatitis C in adultscoinfected with HIV (stable HIV infection), who are serum HCV-RNA positive,including patients with compensated cirrhosis
-
Clinical Benefit
Substantial |
Treatment of HBeAg positive or negative chronic hepatitis B in adults with compensated liver disease
|
Clinical Added Value
no clinical added value |
- Patients with HBeAg positive or negative chronic hepatitis B, with compensated liver disease - Patients with chronic hepatitis C Changes in the SPC relating to the treatment of adult patients coinfected with HCV and HIV (stable HIV infection) do not justify changing the previous Opinion (Committee Opinion of 20 November 2002). |
Contact Us
Évaluation des médicaments